Nebulised Heparin in Patients With COVID-19 Pneumonia
Status:
Not yet recruiting
Trial end date:
2022-10-20
Target enrollment:
Participant gender:
Summary
While the pandemic continues to incite panic and the guideline recommendations regarding
management of COVID continue to change, we have growing evidence that ARDS secondary to
Covid-19 is associated with disseminated intravascular and alveolar fibrin deposition1.
Strategies devised to reduce mucous and fibrin plugs will greatly help in preventing patients
from progressing to invasive ventilation2 which if happens will obviously overburden the
compromised intensive care facilities. Offering heparin in nebulized form has greatly reduced
levels of coagulation activation in the lungs both in animal studies and in patients with
acute lung injury3. As Heparin prevents further fibrin deposition but is ineffective in the
removal of pre-existing fibrin plug, so early use of heparin during the course of the disease
may help in limiting the complications of ARDS and hence reducing the burden faced by our
intensive care units.
A prospective randomized controlled trial will be carried out in patients admitted to COVID
complex to see its effects on disease progression and its role in preventing patients from
progressing to require Invasive Mechanical Ventilation while being administered through local
route rather than systemic. Moreover, it will also give insight and way forward regarding the
improvement in the survival and earlier discharge